Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Pareesh Phulkar

Bookmark and Share
Porphyria Treatment Market Focusing Long-Term Professional Industry
Porphyria is an inherited rare disorder that affects the nervous system or skin and may cause abdominal pain.

BriefingWire.com, 9/13/2019 - Porphyria is an inherited rare disorder that affects the nervous system or skin and may cause abdominal pain. Cells of porphyria patients are unable to change body chemicals called porphyrins and its precursors into heme, the substance responsible for blood color. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the exact rates of porphyria are unknown and vary globally. For instance, porphyria cutanea tarda is most common in the U.S., and variegate porphyria is frequent in South America.

Get PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/1706

Some porphyrias such as erythropoietic protoporphyria, hepatoerythropoietic porphyria, and congenital erythropoietic porphyria occur when an individual receives two abnormal genes, one from each parent. The chances of an individual passing the abnormal gene or genes to the next generation depends on the type of porphyria.

Acute porphyrias affects the nervous system and abdomen. Its attacks develop over hours or days and can last up to several weeks. Cutaneous porphyrias affects the skin. According to the American Porphyria Foundation, acute porphyria affects around 1 to 2 individual per 100,000. High incidence rate was reported in South Africa and Sweden. The foundation promotes comprehensive care necessary for treating individuals with Porphyria. It promotes the disease awareness, reduce the stigma associated with porphyria through physician education, and provides support for those affected. The foundation also organized the Porphyria Awareness Week in April 2018, 21-28.

Porphyria Treatment Market Dynamics

The most common tests used for porphyrias diagnosis are measurements of substances such as porphyrin precursors and porphyrins, in blood plasma, red blood cells, feces, and urine. Measuring enzymes in cells and mutations in DNA is useful for confirmation and family studies. Though, no cure is available for porphyria, there is treatment for each type of the disease. Treatment depends on the type and severity of the disorder and can involve treating with heme, giving medicines to relieve the symptoms, or drawing blood. Drugs like Thorazine,

Chlorpromazine, Panhematin and Hemin can be used to treat symptoms of porphyria. Panhematin (Recordati Rare Diseases) is used for treating acute porphyrias. It is a lyophilized form of alkaline heme that has to be reconstructed immediately before administration and should be infused into a large peripheral vein. As per American Porphyria Foundation, Panhematin is the only commercially available heme therapy in the U.S.

Porphyria Cutanea Tarda (PCT) is the most common and treatable form of porphyria and occurs, due to deficiency of the enzyme, uroporphyrinogen decarboxylase (UROD). PCT is a genetic disorder, however, some people have a genetic (autosomal dominant) deficiency of UROD that results in growth of PCT.

Browse more detail information about: https://www.coherentmarketinsights.com/ongoing-insight/porphyria-treatment-market-1706

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.